Abstract:466 Background: Commonly mutated genes in clear cell renal cell carcinoma include VHL, PBRM1, and BAP1. Although the detection rate of BAP1 mutations in RCC is not high, from an evolutionary perspective. BAP1 mutated renal cell carcinoma tends to have clinical features of higher malignancy, faster disease progression, and poor efficacy of classic drug treatments. Therefore, this study uses our center and TCGA database to analyze the correlation between transcriptome, immune cell infiltration, immune checkpoint expression and other characteristics and the efficacy of immune checkpoint inhibitor-based treatment in patients with BAP1 mutated renal cell carcinoma. Methods: 1. The correlation between the expression of immune-related factors CD4, CD8 and immune checkpoints PD-L1, LAG3 and BAP1 RNA and the expression difference between wild and mutant groups were analyzed through the TCGA database. 2. Collect BAP1 mutant and wild-type patients retrospectively, and verify the expression of CD4, CD8, PD-L1 and LAG3 by immunohistochemistry. 3. The enrichment analysis of the signaling pathway was carried out after the intersection of TCGA and the differential genes of the center. 4. To analyze the clinical curative effect difference between BAP1 wild-type and mutant advanced RCC patients receiving target immunotherapy. Results: The TCGA data confirmed that there was no difference in the expression of PD-L1 RNA between the two groups (P=0.5); while there was a significant difference in the expression of LAG-3 RNA, which was higher in the BAP1 mutant type than in the wild type (P=0.023); 24 cases of BAP1 wild-type ccRCC specimens available in the gene detection database of our center were selected, and the results of immunohistochemistry suggested that there were differences in the expression of LAG3 (p=0.009) between the BAP1 wild-type and mutant types, while PD There was no significant difference in the expression of -L1 (p=0.157). The transcriptome data enrichment analysis results of TCGA and our center database showed that BAP1 was closely related to cytokine signaling, cAMP signaling pathway and immune response signals in the tumor immune microenvironment. In terms of clinical efficacy, the PFS time of BAP1 wild-type RCC patients receiving ICI combined with TKI therapy was significantly longer than that of BAP1 mutant patients (median follow-up time: 23.93 months; median PFS: 24.63 vs. 11.73 months, HR: 0.304, 95%CI: 0.070-1.324, p=0.025). Conclusions: This study found that BAP1 and cytokines, cAMP pathway and immune inflammation-related pathways were significantly enriched at the transcriptome level. IHC results suggested that LAG3 was more highly expressed in patients with BAP1 mutation. Clinical treatment analysis found that PD-1 inhibitor-based immune combination therapy is not effective for patients with BAP1 mutations. In summary, LAG3 may be a potential therapeutic target in the future for patients with BAP1-mutated RCC.

BAP1 loss augments sensitivity to BET inhibitors in cancer cells

BAP1 loss confers sensitivity to bromodomain and extra-terminal inhibitors in renal cell carcinoma

Loss of histone deubiquitinase Bap1 triggers anti-tumor immunity

Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells.

Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN

Tissue-specific Significance of BAP1 Gene Mutation in Prognostic Prediction and Molecular Taxonomy among Different Types of Cancer.

The Tumor Suppressor BAP1 Cooperates with BRAFV600E to Promote Tumor Formation in Cutaneous Melanoma

Bap1 Regulates Cell Cycle Progression Through E2f1 Target Genes and Mediates Transcriptional Silencing Via H2a Monoubiquitination in Uveal Melanoma Cells

Comprehensive Analysis of BAP1 Somatic Mutation in Clear Cell Renal Cell Carcinoma to Explore Potential Mechanisms in Silico

Research advance on BAP1 and its function in tumor suppression

The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK

EZH2 Expression is Increased in BAP1-mutant Renal Clear Cell Carcinoma and is Related to Poor Prognosis

BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition

BET inhibitor suppresses melanoma progression via the noncanonical NF-κB/SPP1 pathway

Reciprocal positive regulation between BRD4 and YAP in GNAQ-mutant uveal melanoma cells confers sensitivity to BET inhibitors

EP1.03-17 Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress

BAP1 Suppresses Prostate Cancer Progression by Deubiquitinating and Stabilizing PTEN

BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas

The immune characteristic analysis of BAP1 mutated clear cell renal cell carcinoma.

Retinoblastoma Protein As an Intrinsic BRD4 Inhibitor Modulates Small Molecule BET Inhibitor Sensitivity in Cancer